Dexcom (DXCM) AI Stock Analysis

• Market Cap: $28.26B
• Dividend Yield: N/A
• Average Volume (3M): 5.11M
• Price to Earnings (P/E): 35.1
• Beta (1Y): 1.10
• Revenue Growth: 14.21%
• EPS Growth: 5.66%
• Country: US
• Employees: 10,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.68
• Shares Outstanding: 384,864,840
• 10 Day Avg. Volume: 4,329,527
• 30 Day Avg. Volume: 5,111,329
• PEG Ratio: 0.66
• Price to Book (P/B): 9.43
• Price to Sales (P/S): 5.56
• P/FCF Ratio: 24.04
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 6.24
• Enterprise Value/Gross Profit: 10.39
• Enterprise Value/Ebitda: 21.78
• 1Y Price Target: $86.94
• Price Target Upside: 18.40% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 20
• EPS Forecast (FY): 2.49
• Revenue Forecast (FY): $5.23B

• Rating: 77 Outperform
• Price Target: $83.00 ▲(13.03% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

DXCM scores well on financial performance (strong growth, profitability, and improved leverage) and is supported by upbeat 2026 guidance emphasizing margin expansion and product catalysts. The overall score is tempered by premium valuation (P/E ~35) and a mixed longer-term technical backdrop with the 200-day average slightly above the current price.

Positive Factors

Revenue Growth & Scale

Multi-year revenue expansion to $4.66B demonstrates durable demand for Dexcom’s CGM platform and recurring sensor sales. Scale improves bargaining power with payers, supports R&D and international rollout, and reduces unit economics sensitivity to single-year fluctuations.

Cash Generation & Balance Sheet Improvement

Material free cash flow and markedly improved leverage provide lasting financial flexibility for R&D, manufacturing investment, M&A or shareholder returns. Strong cash generation reduces refinancing risk and supports execution of multi-year commercialization plans.

Product Innovation Driving Margins

New sensor durability and accuracy (G7 15-day), plus Smart Basal, Stelo and EHR integrations, create sustainable product differentiation. Greater device performance and higher-value features can increase ASPs, reduce scrap/freight costs, and drive structural margin improvement over coming years.

Negative Factors

Competitive & Pricing Pressure

Strong competitors and aggressive payer contracting can structurally compress pricing and mix, pressuring long-run margins and growth even with superior tech. Persistent PBM and international pricing dynamics make margin recovery reliant on sustained product differentiation and payer strategy.

Medicare Coverage Uncertainty

Unclear CMS timing and program design for type 2 non-insulin coverage creates durable demand and reimbursement risk. Delays or unfavorable coverage terms would slow addressable market expansion and alter long-term revenue mix, making multi-year forecasts contingent on regulatory outcomes.

Manufacturing Ramp & Supply Execution Risk

Execution risk from scaling new manufacturing and prior supply issues can persistently affect unit costs, warranty rates and customer availability. Upfront validation and staffing costs weigh on near-term margins and, if ramp problems recur, could delay the structural cost benefits management expects.

Dexcom Business Overview & Revenue Model

Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

How the Company Makes Money

Dexcom generates revenue primarily through the sale of its continuous glucose monitoring systems and related supplies. The company's main revenue streams include the sale of CGM devices, sensors, transmitters, and software applications that enhance user experience and data management. Dexcom also partners with various healthcare providers, insurance companies, and diabetes education programs to promote its products and expand its market reach. These partnerships often lead to increased adoption of Dexcom’s technology among patients and healthcare professionals. Additionally, the company benefits from recurring revenue through the ongoing sales of sensors, which are required for continuous monitoring, thereby creating a stable revenue stream. Dexcom's strategic collaborations with pharmaceutical companies and technology firms further enhance its earnings potential by integrating its solutions with other diabetes management therapies.

Dexcom Financial Statement Overview

Summary

Strong fundamentals supported by steady multi-year revenue expansion to $4.66B (2025), healthy profitability (about 60% gross margin and ~18% net margin in 2025), and improved leverage in 2025 (debt-to-equity ~0.51). Free cash flow exceeded $1.0B in 2025, but margin stability and cash conversion versus net income have been uneven across years.

Income Statement

Revenue expanded steadily from $1.93B (2020) to $4.66B (2025), with a notably strong step-up in 2025 versus 2024. Profitability is healthy for the industry: 2025 gross margin was ~60% and net margin was ~18%, with operating profitability also solid. The main weakness is margin variability over time (gross margin trending lower versus earlier years and net margin swinging sharply in 2020), which suggests earnings quality and cost structure have not been perfectly stable across the cycle.

Balance Sheet

Leverage improved meaningfully in 2025, with debt-to-equity dropping to ~0.51 from ~1.23 in 2024, supported by a higher equity base and lower debt. Returns on shareholder capital are strong (ROE ~30% in 2025), indicating efficient capital use. The key risk is that leverage was elevated for several years prior to 2025 (debt-to-equity ~1.0–1.25), so the balance sheet story is improved but not consistently conservative across the full period.

Cash Flow

Cash generation strengthened materially: operating cash flow rose to ~$1.44B and free cash flow to ~$1.08B in 2025, with healthy growth versus 2024. Free cash flow has improved substantially from the very low 2021 level, supporting reinvestment and balance sheet flexibility. Offsetting this, cash conversion versus accounting earnings is not consistently strong (free cash flow running below net income each year shown), and the operating cash flow-to-net-income relationship has been uneven across years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.66B	4.03B	3.62B	2.91B	2.45B
Gross Profit	2.80B	2.44B	2.29B	1.88B	1.68B
EBITDA	1.16B	945.70M	916.70M	565.30M	377.50M
Net Income	836.30M	576.20M	541.50M	341.20M	216.90M
Balance Sheet
Total Assets	6.34B	6.48B	6.26B	5.39B	4.93B
Cash, Cash Equivalents and Short-Term Investments	2.00B	2.58B	2.72B	2.46B	2.73B
Total Debt	1.39B	2.59B	2.59B	2.15B	2.16B
Total Liabilities	3.59B	4.38B	4.20B	3.26B	2.89B
Stockholders Equity	2.75B	2.10B	2.07B	2.13B	2.04B
Cash Flow
Free Cash Flow	1.08B	630.70M	511.90M	304.70M	53.30M
Operating Cash Flow	1.44B	989.50M	748.50M	669.50M	442.50M
Investing Cash Flow	536.00M	-207.50M	-507.20M	-521.50M	-216.10M
Financing Cash Flow	-1.69B	-734.80M	-318.60M	-552.50M	10.40M

Dexcom Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 73.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXCM, the sentiment is Positive. The current price of 73.43 is above the 20-day moving average (MA) of 71.27, above the 50-day MA of 70.07, and below the 200-day MA of 73.85, indicating a neutral trend. The MACD of 0.96 indicates Negative momentum. The RSI at 58.00 is Neutral, neither overbought nor oversold. The STOCH value of 88.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DXCM.

Dexcom Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$28.26B	35.09	34.50%	―	14.21%	5.66%
EW	75 Outperform	$50.22B	47.87	10.43%	―	0.19%	65.58%
SNN	69 Neutral	$15.66B	32.64	9.20%	2.28%	5.78%	61.52%
STE	69 Neutral	$24.75B	34.91	10.44%	0.94%	5.15%	60.30%
PODD	68 Neutral	$17.36B	70.45	18.12%	―	27.12%	-41.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	45 Neutral	$1.73B	-8.24	-97.88%	―	17.87%	-57.03%

Dexcom Corporate Events

Dexcom Adds Google Executive Rick Osterloh to Board

On February 26, 2026, Dexcom’s board expanded to twelve members and appointed Rick Osterloh, Google’s Senior Vice President for Platforms & Devices, as an independent director with a term running until the 2026 annual shareholder meeting. He joins the Compensation and Technology committees, receives standard director indemnification, and was granted restricted stock units under Dexcom’s non-employee director compensation program, aligning his incentives with long-term shareholder interests.

Osterloh’s appointment brings deep expertise in consumer hardware, platforms, and large-scale product operations from his leadership roles at Google, Motorola, and other major technology firms. Dexcom’s leadership highlighted that his experience integrating advanced hardware, software, and AI should support the company’s long‑term product strategy in biosensing and metabolic health, potentially strengthening its innovation pipeline and competitive position in digital health and wearables.

The most recent analyst rating on (DXCM) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.

Dexcom Names Jacob Leach as Incoming Chief Executive

Dexcom’s board has confirmed that President and Chief Operating Officer Jacob S. Leach will assume the roles of President, Chief Executive Officer and director effective January 1, 2026, following the previously announced resignation of long-time CEO Kevin R. Sayer as of that date. On December 19, 2025, Leach agreed to an offer package that includes a $1,150,000 annual base salary, a target annual bonus equal to 150% of base pay, $7.5 million in time-vested restricted stock units over three years, and $7.5 million in performance stock units contingent on meeting compensation committee–set performance goals, while remaining eligible for existing executive severance and benefit plans; the board expects Sayer to return from medical leave around March 2026 to resume his role as board chairman, with Mark Foletta serving as interim chair in the meantime, signaling continuity in the company’s leadership transition and governance structure.

The most recent analyst rating on (DXCM) stock is a Buy with a $78.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.